PubMed Health⌕ Search

Biomedical subjects

E Smart

Publications and source records attributed to E Smart.

27 records · Page 2Linked to original sources
PubMed1991

Serology and genetics of the red blood cell factor Rh34.

Rh34 antibodies were found to have a unique, previously only partly characterised, specificity within the Rh system. No evidence was seen that they were mixtures of hrB and Hr-like antibodies, or that hrB antibodies existed independently in the natural state. The term anti-hrB applied to Rh34 antibodies after they had been partially absorbed with R2R2 red cells. Four haplotypes not expressing Rh34 antigen were identified in the present study. The prefix * has been used to indicate them in this text. They were *r's (*dCces), *Ro (*Dce), *Rou (*D(uce)) and *R(od) (category III *Dce). Red cells with partially deleted or Rh(null) phenotypes were therefore not the sole red cells compatible with anti-Rh34. R2R2 red cells, which are known to carry weak Rh34 antigen, were incompatible. Twenty-two family and mother-child studies established that the Rh:-34 haplotypes were inherited as normal Mendelian dominant characters. Anti-Rh34 was capable of recognising RH 34 dosage and of excluding some men who had been wrongly accused in disputed paternity tests.

Adult↗
PubMed1991

D-- and Dc- gene complexes in the coloureds and blacks of Natal and the eastern Cape and blood group phenotype and gene frequency studies in the Natal coloured population.

Following the detection of apparent exclusions in the Rh system in two Coloured (mixed race) families during paternity testing, a rare D-- gene complex was identified in one family and two examples of an unusual gene complex producing weak e and very weak or non-demonstrable f antigen in the other. The latter, which almost certainly belong to the heterogeneous collection known as Dc-, were found when the Rh phenotypes expected to give f+, instead gave f- or f+W (weak positive) results and those expected to give f-, gave f+W results. Blood group phenotype and gene frequency studies showed that the Natal Coloured population contains a mixture of approximately 40% Black, 30% White and 30% Indian (Asian) genes. The phenotypes A1 high H, B high H, B low H, K+ and Kp(a+) associated with Caucasoids and the phenotypes Abantu, Dantu+, hrS- (Rh: -18,-19), hrB- (Rh: -31,-34) and Fy(a-b-) associated with Negroids were all represented. The DCe/Dc- frequency was 6.9% and the DcE/Dc- frequency 2.6%.

Black People↗
PubMed1990

Wd(a+) red blood cells in two sisters of a Hei//om Khoisan family in Namibia.

Two sisters in a Hei//om family of the southern African Khoisan race in Namibia were found to have Wd(a+) red blood cells. Wda is a low-frequency antigen identified so far only in a European family in Canada and a family in Holland. The Wda gene may have had an independent origin in the Khoisan. Alternatively, the Hei//om population may have acquired it through miscegenation.

Blood Group Antigens↗
PubMed1988

Regulation of the number of alpha-bungarotoxin binding sites in cultured chick myotubes by a 1,4 dihydropyridine calcium channel antagonist.

Calcium has been suggested as the second messenger link between skeletal muscle activity and AChR gene expression and synthesis. We have compared the concentrations of the Ca2+ channel antagonists D600 and nisoldipine needed both to block Ca2+ uptake into cultured myotubes and to increase AChR expression. The good correspondence between these two measurements and the use of the highly specific Ca2+ channel antagonist nisoldipine strengthens the hypothesis that AChR expression is regulated by levels of intracellular Ca2+.

3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethy↗
PubMed1981

A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.

We randomized 96 postmenopausal women with metastatic breast carcinoma to receive surgical adrenalectomy or medical therapy with an adrenal inhibitor, aminoglutethimide (AG), plus replacement hydrocortisone. Before randomization, women were stratified according to disease-free interval, site of dominant disease, and estrogen-receptor status. Of 40 evaluable women treated with AG and hydrocortisone, 53 per cent had objective responses, as compared with 45 per cent of 29 women undergoing surgical adrenalectomy (P value not significant). Responses lasted a mean of 17.2 months in the medical group and greater than 17.1 months in the surgical group (not significant). Estrogen levels fell similarly in response to either treatment, whereas AG and hydrocortisone preserved androgen production. A null hypothesis tested the single question asked by this study: "Is surgical adrenalectomy superior to treatment with AG and hydrocortisone?" Rejection at significance levels of P = 0.01 and P = 0.07 for differences of 20 per cent and 10 per cent, respectively, suggested that medical therapy with AG and hydrocortisone may be logically chosen in place of surgical adrenalectomy.

Adrenalectomy↗